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Novel HLA Class I Alleles Outside the Extended DR3
Haplotype Are Protective against Autoimmune Hepatitis
Craig Lammert, MD1, Elizabeth J. McKinnon, PhD2, Naga Chalasani, MD1 and Elizabeth J. Phillips, MD3
INTRODUCTION: HLA class II allele, DRB1*03:01, is the most common genetic risk factor for autoimmune hepatitis
(AIH), but other unrecognized HLA related risks exist.
METHODS: We compared the HLA class I (A, B, C) and class II (DR, DQ, DP) typing between patients with well-
characterized AIH and healthy controls by high resolution sequencing of the HLA region. Seventy-three
patients with AIH and 87 healthy controls were included. Association betweenHLA alleles and AIHwas
considered singly and in clusters and adjusted for age, gender, and DRB1*03:01.
RESULTS: DRB1*03:01 was singly associated with AIH among whites (odds ratio [OR]: 3.09, P 5 0.002) and
carriers of DRB1*03:01 also carried DQA*05:01 and DQB1*02:01. Significant HLA class I alleles
were associated with AIH including those belonging to the A03 (OR: 0.4, P5 0.01) and B44 supertype
(OR: 0.44, P5 0.03). Further refinement of HLA-A by binding pocket structure revealed that the
sequence Y(F/T)AVMENV(H/Q)Y, corresponding to HLA-A alleles A*03:01-02; *31:01; *32:02, was
protective for AIH (OR: 0.3,P50.002). A protective association also existed for alleles belonging to the
HLA-B binding pocket structure Y(H/Y)TVKEISNY (OR: 0.35, P5 0.01), corresponding to HLA-B
alleles: B*40:01-02; *41:02; *44:02-03; *45:01; *49:01; *50:01-02. Associations with specific
class I alleles belonging to the 8.1 ancestral haplotype (HLA-A*01:01, HLA-B*08:01,HLA-C*07:01)
were not significant when considered jointly with DRB1*03:01 and reported protective class I alleles.
DISCUSSION: Our study identified novel supertypes and HLA-A and B peptide binding structures protective against
AIH. Further risk assessment of class I molecules remains important in AIH as they are keymediators of
adaptive immunity.
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INTRODUCTION
Autoimmune hepatitis (AIH), despite being a rare disease with
estimated prevalence at 16–18 people per 100,000 (1–3), aﬀects all
population demographics and is increasing in incidence (4). It is
characterized by immune-mediated destruction of hepatocytes
along with serum antibodies such as anti-nuclear antibody and
anti-smooth muscle antibody (5) and can result in progressive
ﬁbrosis, liver failure, and death (6). There is marked phenotypic
heterogeneity associated with AIH as exempliﬁed by a spectrum
of autoantibody proﬁles (7), clinical symptoms at presentation
(8), and response to treatment medication (9).
The HLA locus is currently the most important genetic con-
tribution to AIH (10). The HLA region on chromosome 6 is
comprised of major histocompatibility complex class I and II
genes and has been strongly associated with risk for many auto-
immune diseases (11). The results from the only AIH genome-wide
association study have reported one strict association rooted in the
HLA locus (rs2187668, odds ratio [OR]: 2.9; P 5 1.3 3 10248), an
eﬃcient tagging SNP for DRB1*0301 (10). Alleles at this position
encode the antigen-binding groove of class II molecules and can
inﬂuence binding of antigens presented to native CD41 helper
T lymphocytes (12). Although historical studies (13) have linked
HLA-DRB1 with AIH risk, a thorough investigation of the HLA
locus has not been conducted. All HLA-associated disease risk
cannot be explained byDRB1, as diﬀerent alleles can portray risk or
protection in diﬀerent populations (14). In addition, top risk alleles
encode identical residues (DRb71) and yet have been associated
with diﬀerent clinical outcomes (15).
Poor locus resolution in prior genetic studies and high linkage
disequilibrium within the region are a major challenge to clarify
the role of HLA-associated risk in AIH (16). Furthermore, class I
molecules within the HLA region also remain understudied in
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many autoimmune diseases. These molecules can interact closely
with killer immunoglobulin-like receptors (KIRs) to activate
natural killer cells, key mediators of adaptive immunity (17–19),
and hepatotropic viral replication (20). Therefore, we aimed to
compare HLA class I (A, B, C) and class II (DR, DQ, DP) typing
between patients with well-characterized AIH and healthy con-
trols by high resolution sequencing of the HLA region.
METHODS
Genetic repository of autoimmune liver diseases and
contributing exposures cohort
The genetic repository of autoimmune liver diseases and contributing
exposures (GRACE) cohort (21), established in 2014 at Indiana
University (IU),wasdeveloped inorder to strategicallywarehouse and
link biospecimens, high quality clinical data, and environmental ex-
posure histories among autoimmune liver disease patients. AIH
patients (cases) included in the GRACE cohort included both man
andwomanmore than18yearsofagewithadiagnosisofAIHmeeting
the criteria established by the International Group for the Study of
AIH (22). Cases were excluded if other etiologies of liver disease were
present (e.g., viral hepatitis, alcoholic liver disease, nonalcoholic stea-
tohepatitis, and hemochromatosis, etc.). Cases were serially recruited
from patients with well-deﬁned AIH who were attending IU liver
clinics and hospitalized within the IU hospital system.
Controls
Study controls were identiﬁed from patients enrolled in the
Indiana Biobank (IB). The IB, established in 2010, is an estab-
lished repository of biologic samples linked to the Indiana Net-
work for Patient Care, a health information exchange that
contains data contributed by multiple Indiana healthcare insti-
tutions, by medical record number, and other demographics.
Controls had historically normal alanine aminotransferase levels
per the Prati criteria (23) and normal aspartate aminotransferase,
alkaline phosphatase, and total bilirubin at time of IB collection.
DNA collection and isolation
Study DNA was extracted from stored saliva collected in the
Oragene Saliva Kit which contains a stabilizing solution. DNA
was extracted using the AutoGen Flex STAR. It provides a pure
DNA sample using Flexigene chemistry that employs an initial
process that pellets the white cell nuclei and mitochondria while
simultaneously lysing the red cells. During the next step, it
denatures and eliminates the proteins and cellular material uti-
lizing a protease enzyme.
HLA sequencing and binding pocket structure
All samples required at least 2.5mg ofDNAat a concentration of 50
ng/mL in EDTA buﬀer to complete sequencing. HLA loci was
polymerase chain reaction ampliﬁed using sample speciﬁc multi-
plex identiﬁer (MID)-tagged primers that amplify polymorphic
exons from class I (A, B, C exons 2 and 3) and class II (DQ, exons 2
and 3; DRB and DPB1, exon 1) major histocompatibility genes.
AmpliﬁedDNAproducts fromuniqueMID-taggedproducts (up to
48 MIDs) were pooled in equimolar ratios and subjected to library
preparation. Libraries will be quantiﬁed using the KAPA library
quantitation kit (Roche Kapa Biosystems, Wilmington, MA) and
High sensitivity D1000 screentape on an Agilent 2,200 Tapestation
(Agilent Scientiﬁc Instruments, Savage,MD) for concentration and
size distribution. Normalized libraries were sequenced on the Illu-
mina MiSeq platform using the MiSeq V3 600-cycle kit (Illumina,
Inc., San Diego, CA). Sequences were separated by MID tags and
alleles called using an accredited HLA allele caller software pipeline
that minimizes the inﬂuence of sequencing errors. Alleles were
called using the latest International ImMunoGeneTics HLA allele
database as a reference library. Samples to report integrity were
checked using proprietary and accredited laboratory information
andmanagement system. Furthermore, the HLA analyse reporting
software performs comprehensive allele balance and contamination
checks on the ﬁnal dataset.
Statistical considerations
Descriptive statistics were reported as means and SDs or percen-
tages. HLA allelic associations with cases and controls were con-
sidered both singly and in clusters deﬁned by haplotype, supertype,
and binding pocket structure. Initially, HLA-speciﬁc diﬀerences
between cases and controls were assessed by Fisher’s exact test.
Multivariable logistic regression analyses adjusted for age, gender,
and ethnicitywere then utilized to further explore these associations
and provide Odds ratios (OR) with 95% conﬁdence intervals.
RESULTS
Cohort characteristics
Seventy-threewell-phenotyped cases,with an average age at time of
AIH diagnosis of 44.4 years, were included in the analysis. A ma-
jority of the cases were women (81%) and white (90.4%). Eighty-
seven controls were included in this study. The controls were no
diﬀerent than cases according to sex (87%) and ethnicity (94.3%)
(Table 1); however, the age of enrollment into the GRACE cohort
was lower for the controls (45 vs 53 [mean age in years], P5 0.05).
Among cases, anti-nuclear antibody was positive in 59%, 94% had
a positive (1:40) anti-smoothmuscle antibody, and no patients had
a positive liver kidney microsomal antibody within 6 months of
AIH diagnosis. The mean of the alanine aminotransferase at AIH
diagnosis was 546 U/L (638), aspartate aminotransferase: 458 U/L
(552), total bilirubin: 4.9 mg/dL (7.1), international normalized
ratio: 1.16 (0.16), and immunoglobulin G: 2,014 mg/dL (883).
HLA alleles, supertype, and binding pocket
In order to eliminate ethnically derived polymorphic allele con-
tributions to HLA, only white cases were included in this analysis
(66 cases and 82 controls) (Table 2 ). Forty-nine cases (74%) had at
least oneof thepreviously identiﬁed riskallelesHLA*03:01 or *04:01
compared to34 (41%) controls (P50.05). IndividuallyDRB1*03:01
was strongly associated with AIH (OR: 3.09, P 5 0.002), yet
DRB1*04:01, was only observed to have marginal additional risk in
cases (OR: 1.6, P 5 0.1). All carriers of DRB1*03:01 also carried
DQA*05:01 and DQB1*02:01, as is consistent with the DR3
haplotype.
Table 1. Demographics of AIH cases and healthy controls
Cases
(n5 73)
Control
(n5 87) P value
Sex (% woman) 81 87 NS
Age (yr) at enrollment, mean (SD) 53 (16) 45 (13) 0.05
Race (% white) 90.4 94.3 NS
Age (yr) at AIH diagnosis, mean (SD) 44.4 (17) — —
AIH, autoimmune hepatitis; NS, not significant.
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HLA class 1 allelic diﬀerences between cases and controls
included the consideration of the supertype grouping and peptide
binding structure of the HLA molecule. Alleles belonging to the
A03 (37.9% vs 57.3%, P5 0.02) and B44 (28.8% vs 50%,P5 0.01)
HLA supertype were observed less frequently among cases
compared to controls. Further reﬁnement of the class I molecules
by binding pocket structure revealed that the amino acid se-
quence Y(F/T)AVMENV(H/Q)Y, corresponding to HLA-A
alleles A*03:01-02; *31:01; *32:02, was protective for AIH (OR:
0.3, P 5 0.002). Another protective association also existed for
alleles belonging to the HLA-B binding pocket structure Y(H/Y)
TVKEISNY (OR: 0.35, P 5 0.01), corresponding to HLA-B
alleles: B*40:01-02; *41:02; *44:02-03; *45:01; *49:01; *50:01-02.
Associations with speciﬁc class I alleles belonging to the 8.1 an-
cestral haplotype (HLA-A*01:01, HLA-B*08:01, HLA-C*07:01)
was not signiﬁcant when considered jointly withDRB1*03:01 and
reported protective class I eﬀects.
DISCUSSION
We utilized a well-described AIH cohort to conﬁrm the histori-
cally observed (24,25) associations between HLA-DRB1 alleles
andAIH.Weprovide an initial in depth assessment ofHLAclass I
genes that identify an independent yet disease protective eﬀect of
HLA-A alleles *03:01-02;*31:01;*32:02 and HLA-B alleles *40:01-
02;*41:02;*44:02-03;*45:01;*49:01;*50:01-02. Furthermore, we
describe related class I supertypes and binding pocket structures
that encompass these protective alleles. Despite a well-described
history of variable HLA-DRB1 disease risk and protection across
ethnically diverse populations with AIH (8,10,24), our data sug-
gest genetic risk with the HLA locus expands beyond the class II
genes in whites. Further dissection and clariﬁcation of a more
complete HLA risk association with AIH will help provide
a comprehensive understanding of AIH pathogenesis and assist
with future strategies aimed at improving diagnosis and in-
dividualized treatment strategies.
AIH is undoubtedly a polygenic disorder for which the HLA
locus is themost important genetic contribution. The results from
the only AIH genome-wide association study revealed only one
strict genetic association rooted in theHLA locus (rs2187668, OR:
2.9; P 5 1.3 3 10248) (10). Historically, candidate gene studies
have also supported this ﬁnding as well as DRB1*0401 as major
susceptibility alleles in AIH among both European and North
American patients (26).We conﬁrmed this associationwithin our
AIH cohort, as nearly 75% of our cases had at least one copy of
alleles DRB1*0301 or *0401 (Table 2). These alleles share the 71K
amino acid polymorphism, encoding the LLEQKR amino acid
sequence at 67–72 in the antigen-binding groove of class II
molecules. Class II molecules are highly prevalent on antigen
presenting cells, thus are likely to exert a strong inﬂuence on the
diversity of antigens presented to native CD41 helper
T lymphocytes (8,12,24). However, not all HLA-associated AIH
risk can be solely explained by DRB1 as diﬀerent alleles can
portray risk or protection in diﬀerent populations (27,28). In
addition, these top risk alleles encode identical residues (DRb71)
and have been associated with diﬀerent clinical outcomes (15).
Despite current and previously identiﬁed HLA risk alleles, the
impact of HLA architecture on AIH heterogeneity remains in-
completely elucidated. An integrative approach will be required
to overcome these disease gaps and will require high-quality ex-
posure data with longitudinal measures, detailed phenotyping,
and inclusion of diverse ethnic and geographic populations.
Poor locus resolution and high linkage disequilibrium within
theHLA region have been signiﬁcant challenges to clarify the role
of HLA-associated risk in AIH (16). Class I gene studies in AIH
remain incomplete, as only few AIH studies have supported the
class I allelic risks typically within the context of the ancestral
haplotype (HLA-B8, DR3, DQ2) (29,30). Recently, a possible
novel role of class I genetic risk in AIH etiopathogenesis was
described mechanistically via the KIRs stimulation of natural
killer (NK) cells (18). Downstream regulation ofNK cells depends
highly upon the interaction ofKirs and their ligands, namelyHLA
class I molecules. Littera et al. (18) not only observed an associ-
ation of HLA-B*18:01 within a Sardinian AIH cohort but also
identiﬁed a low frequency of HLA-Bw4 KIR ligands and over-
expression of a group of C2 KIR ligands in AIH cases. Further-
more, pediatric onset AIH, a typically more aggressive form of
disease, withKIR2DS4-Full Length ligand has been observedwith
Table 2. HLA associations with autoimmune hepatitis among whites
HLA carriage
Cases Controls Unadjusted Adjusted
a
N (%) N (%) OR P OR P
HLA-DRB1
03:01a 34 (51.5) 21 (25.6) 3.09 0.002 3.25 0.002
04:01a 15 (22.7) 13 (15.9) 1.56 0.3 2.06 0.1
HLA-A
A03 supertype 25 (37.9) 47 (57.3) 0.45 0.02 0.4 0.01
B pocket: Y(F/T)AVMENV(H/Q)Yb 16 (24.2) 40 (48.8) 0.34 0 0.3 0.002
HLA-B
B44 supertype 19 (28.8) 41 (50.0) 0.4 0.01 0.44 0.03
B pocket: Y(H/Y)TVKEISNYc 14 (21.2) 36 (43.9) 0.34 0.01 0.35 0.01
aLogistic regression, djusting for carriage of DRB1*03:01, age and sex.
bCommon amino acids across key positions of the B binding pocket: p7-p9-p24-p34-p45-p63-p66-p67-p70-p99. HLA-A alleles A*03:01-02; *31:01; *32:02.
cHLA-B alleles: B*40:01-02; *41:02; *44:02-03; *45:01; *49:01; *50:01-02. Common amino acids across key positions of the B binding pocket: p7-p9-p24-p34-p45-
p63-p66-p67-p70-p99.
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increased frequencies of HLA-C*02, 04, and 06 (31). Thus, it not
only remains highly likely that HLA class I molecules are critical
for the immunologic diﬀerentiation of self vs nonself via a tradi-
tional CD4/CD8 T cell-mediated model, but also may impact
innate immunity and regulation of adaptive immune responses
via NK cell activation in diﬀering phenotypic types of AIH.
We observed key diﬀerences between cases and controls
according to A03 and B44 supertypes that correlated with speciﬁc
peptide binding structures within the class I molecules (Table 2).
Our observation supports an additive risk to AIH in white patients
beyond the traditional class II genetic risks and necessitates further
dissection of the class I role in AIH pathogenesis. Disease suscep-
tibility linked to Kir genes has been reported in other autoimmune
liver diseases as well, such as primary sclerosing cholangitis (32).
Karlsen et al. (32) reported similar Kir gene frequencies among
primary sclerosing cholangitis (PSC) and controls but with a re-
duction of ligands to inhibitoryKirs 3DL1 and 2DL1.AIH andPSC
both share an associationwith the 8.1 ancestral haplotype inwhites,
which includes DRB1*0301. Other key HLA associations within
PSC, speciﬁcally genes HLA-B8 and HLA-DR13, have not been
observed as independent risk factors for AIH (5). There is also risk
overlap at the DRB1 gene in primary biliary cholangitis; however,
primary biliary cholangitis has also been historically associated
with risk alleles in HLA-DQB1 in whites (33).
Environmental exposures, an integral part to overall disease
risk in many complex autoimmune diseases (34,35), also ﬁt well
with this model given strong associations with hepatrophic viral
exposure and autoimmune liver diseases (36,37).
We admit our study does have few limitations, yet we strongly
believe these have little impact on the key experimental ﬁndings.
Despite an overall low study number, we enriched the cohort by
ensuring a highly accurate phenotype of all AIH cases and controls.
In order to eliminate other genetic confounding, we also only in-
cluded patients that were white in the ﬁnal analysis. We do not
believe that a study with this scope will ultimately disentangle HLA
contributions to AIH, but we do believe it is an integral step in the
clariﬁcation of HLA-associated disease risk. We only completed
deep sequencing of the HLA region, as we believe data to date
suggests the HLA region is the area most likely to yield the largest
eﬀect size for the risk of AIH. We plan to expand up this study
cohort, include all ethnicities, and integrate other key environmental
contributions and HLA-environment interactions, as this likely
more accurately describes the underpinning to AIH pathogenesis.
In conclusion, broken tolerance and failure of immunologic
homeostasis in AIH are likely the result of permissive HLA archi-
tecture within a wide array of environmental triggers, but this
pathogenesis paradigm remains poorly understood. We report
results of HLA class I/II sequencing within a well-described adult
white AIH cohort. Our data support historical associations between
AIH and HLA-DRB1 alleles as well as identiﬁes new ﬁndings of
independent and protective HLA-A andHLA-B alleles. Elucidation
of the HLA architecture in AIH will certainly provide a more com-
prehensive understanding of disease pathogenesis but may also pro-
mote an individualized approach to treatment and management.
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